Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice (vol 34, pg 563, 2015)

被引：0
|
作者：
Bykerk, Vivian P. [1 ,2 ]
Oestoer, Andrew J. K. [3 ]
Alvaro-Gracia, Jose [4 ]
Pavelka, Karel [5 ]
Roman Ivorra, Jose Andres [6 ]
Graninger, Winfried [7 ]
Bensen, William [8 ]
Nurmohamed, Michael T. [9 ]
Krause, Andreas [10 ]
Bernasconi, Corrado [11 ]
Aassi, Maher [11 ]
Sibilia, Jean [12 ]
机构：
[1] Hosp Special Surg, Inflammatory Arthrit Ctr, New York, NY 10021 USA
[2] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada
[3] Univ Cambridge, Cambridge, England
[4] Hosp Univ Princesa, IIS Princesa, Madrid, Spain
[5] Inst Rheumatol, Prague, Czech Republic
[6] Hosp Univ La Fe, Valencia, Spain
[7] Med Univ Graz, Graz, Austria
[8] McMaster Univ, St Josephs Hosp, Hamilton, ON, Canada
[9] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[10] Immanuel Hosp, Berlin, Germany
[11] F Hoffmann La Roche, Basel, Switzerland
[12] CHU Hautepierre, F-67098 Strasbourg, France
来源：
CLINICAL RHEUMATOLOGY | 2015年 / 34卷 / 07期
关键词：
D O I：
10.1007/s10067-015-2932-z
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1321 / 1321
页数：1
相关论文
共 39 条
  • [31] Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
    Doerner, T.
    Schulze-Koops, H.
    Burmester, G. -R.
    Iking-Konert, C.
    Schmalzing, M.
    Engel, A.
    Kaestner, P.
    Kellner, H.
    Kurthen, R.
    Krueger, K.
    Rubbert-Roth, A.
    Schwenke, H.
    Peters, M. A.
    Tony, H. -P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (06) : 937 - 945
  • [32] Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor (vol 36, pg 190, 2016)
    Abdulkader, Omer Ahmad Fatheddin
    Qushmaq, Khalid
    Aljishi, Faiza
    ANNALS OF SAUDI MEDICINE, 2017, 37 (04) : 339 - 339
  • [33] Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
    Bower, Hannah
    Frisell, Thomas
    di Giuseppe, Daniela
    Delcoigne, Benedicte
    Askling, Johan
    RMD OPEN, 2023, 9 (04):
  • [34] Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.
    Aramaki, Toshiyuki
    Ueki, Yukitaka
    Kojima, Kanako
    Kurushima, Shota
    Tsuji, Yoshika
    Kawachi, Natsumi
    Iwamoto, Naoki
    Ichinose, Kunihiro
    Terada, Kaoru
    Eguchi, Katsumi
    Kawakami, Atsushi
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 50 - 57
  • [35] Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
    Sebnem Ataman
    Ismihan Sunar
    Hatice Bodur
    Meltem Alkan Melikoglu
    Hasan Fatih Cay
    Erhan Capkin
    Ozgur Akgul
    Remzi Cevik
    Feride Gogus
    Ayhan Kamanli
    Fatma Gul Yurdakul
    Gulcan Gurer
    Ilker Yagci
    Aylin Rezvani
    Mehmet Tuncay Duruoz
    Rheumatology and Therapy, 2022, 9 : 223 - 241
  • [36] Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
    Ataman, Sebnem
    Sunar, Ismihan
    Bodur, Hatice
    Melikoglu, Meltem Alkan
    Cay, Hasan Fatih
    Capkin, Erhan
    Akgul, Ozgur
    Cevik, Remzi
    Gogus, Feride
    Kamanli, Ayhan
    Yurdakul, Fatma Gul
    Gurer, Gulcan
    Yagci, Ilker
    Rezvani, Aylin
    Duruoz, Mehmet Tuncay
    RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 223 - 241
  • [37] Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies (vol 54, pg 1226, 2015)
    Kvamme, Maria K.
    Lie, Elisabeth
    Uhlig, Till
    Moger, Tron A.
    Kvien, Tore K.
    Kristiansen, Ivar S.
    RHEUMATOLOGY, 2020, 59 (04) : 917 - 917
  • [38] Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis (vol 70, pg 266, 2010)
    Salliot, Carine
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (03) : 660 - 660
  • [39] Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
    Fleischmann, Roy
    Cutolo, Maurizio
    Genovese, Mark C.
    Lee, Eun Bong
    Kanik, Keith S.
    Sadis, Seth
    Connell, Carol A.
    Gruben, David
    Krishnaswami, Sriram
    Wallenstein, Gene
    Wilkinson, Bethanie E.
    Zwillich, Samuel H.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (03): : 617 - 629
1234